(NASDAQ: RANI) Rani Therapeutics Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.95%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.76%.
Rani Therapeutics Holdings's revenue in 2023 is $0.On average, 1 Wall Street analysts forecast RANI's revenue for 2026 to be $3,002,085,418, with the lowest RANI revenue forecast at $3,002,085,418, and the highest RANI revenue forecast at $3,002,085,418. On average, 2 Wall Street analysts forecast RANI's revenue for 2027 to be $7,753,001,588, with the lowest RANI revenue forecast at $3,821,464,207, and the highest RANI revenue forecast at $11,684,538,969.
In 2028, RANI is forecast to generate $18,161,086,612 in revenue, with the lowest revenue forecast at $6,610,807,300 and the highest revenue forecast at $29,711,365,924.